2007.12.10 NVAX

Pre-market:

NVAX - +13% gap a pre-marketben...

Market open:

AMGN esik....




CELG esik...



Megjegyzendő azonban, hogy túl sokat esett az első 5 percben...
Ennek ellenére a napi minimum 47 dollár körül alakult...

A vetélytárs MLNM sikeres gyógyszerkísérletének hírére esett...:

"Millennium Pharma Reports Positive Results On Velcade In Phase III VISTA Trial - Quick Facts

(RTTNews) - Millennium Pharmaceuticals Inc. (MLNM) said the results from a Phase III VISTA trial showed that Velcade, melphalan and prednisone or VcMP demonstrated statistical significance in overall survival with a 40% reduction in risk of death.

The Phase III VISTA trial involved 682 patients, who were ineligible for stem cell transplantation or SCT with previously untreated multiple myeloma or MM. The trial compared Velcade, melphalan and prednisone to melphalan and prednisone or MP alone, a recognized standard of care in this treatment setting.

The company said the trial has achieved the highest reported complete remission rate of 35% in a front-line multiple myeloma trial with Velcade or bortezomib for injection based therapy.

The company presented these data at the annual meeting of the American Society of Hematology.

The company said it will file a sNDA this month to seek approval to this treatment setting, which could significantly increase the number of patients eligible to benefit from Velcade."

Az AMGN meg ezért:

"Amgen Lower On Safety Updates

(RTTNews) - Amgen Inc. (AMGN) slid more than 5% on Friday after the company revealed that it was in talks with the FDA to update the safety information on all ESAs. The stock gapped open lower and slid further through mid-morning trading. With a further dip going into the close, AMGN closed at $52.10, down $3.05."

Market closed